Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies

NCT02922764 is registered in ClinicalTrials.gov with Inspirna, Inc. as lead sponsor.

NCT NCT02922764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02922764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies
Lead sponsor
Inspirna, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2016
Completion date
January 22, 2025
Enrollment
146 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, endometrial cancer recurrent, lung cancer, lung cancer recurrent, non-small cell carcinoma, non-small cell lung cancer metastatic